Pfizer reported better-than-expected quarterly results, driven by lower taxes and sales of generic medicines, but revenue from its branded patent-protected medicines brought disappointment.

Pfizer yesterday reported profit that beat analysts’ estimates after sales of Lyrica, a pain drug, and Ibrance, a breast cancer treatment, outperformed expectations. The company also raised its 2015 sales and profit outlook.